This has been a year of transformative progress and meaningful impact at Gilead. As 2024 comes to a close, we’re looking back on some of our exciting milestones and looking forward to helping make the world a healthier place for all people in 2025. #GileadLife
Gilead Sciences
Biotechnologieforschung
Foster City, CA 659.869 Follower:innen
Creating Possible
Info
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
- Website
-
http://www.gilead.com
Externer Link zu Gilead Sciences
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Foster City, CA
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1987
Orte
Beschäftigte von Gilead Sciences
Updates
-
We’re proud to be included on the Dow Jones Sustainability World Index and to be recognized as one of the most sustainable pharmaceutical companies. This is the fourth year we’ve been included on the list, and it reflects our commitment to sustainable business practices and transparency on environmental, social and governance issues. By investing in world-class science, improving access to our therapies and breaking down barriers to care, we’re helping create a healthier world for all people. Learn more about our commitments in our ESG Impact Report: https://gilead.inc/3ZLVGIO
-
-
#InTheNews: The Global Fund and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) today announced a coordinated effort to provide affordable and equitable access to our investigational twice-yearly medication for #HIV prevention, if approved. The plan is to enable access for at least 2 million people over three years. https://gilead.inc/3DeZP00
-
Our culture of inclusion and diversity fuels innovation and allows us to connect with and uplift the communities we serve around the world. We’re honored that this commitment, which begins with our Board of Directors, has been recognized with a 2024 DE&I Award from the NACD (National Association of Corporate Directors).
-
At #SABCS24, we sparked a meaningful conversation about the role of supportive care for those diagnosed with metastatic breast cancer. We left inspired to continue our efforts to help create a healthier world where people living with cancer receive the support they deserve from diagnosis and beyond.
-
-
#GileadNews: Today, we received a positive opinion from the #CHMP for a novel treatment for adults with #PrimaryBiliaryCholangitis. This is an important step in providing another treatment option for people living with PBC in Europe. Read more: https://gilead.inc/3OVyDG8
-
Today, we’re pleased to announce that Dietmar Berger has been named our new Chief Medical Officer. An internist, hematologist and oncologist with more than 25 years of experience in developing and delivering innovative medicines across therapeutic areas, Dietmar will assume his role on Jan. 2. https://gilead.inc/3ZPVjxN
-
Our investigational twice-yearly medication for #HIV prevention has been named the 2024 Breakthrough of the Year, an annual honor that Science Magazine gives to important and influential developments in science. Our medication has the potential to fill critical gaps in HIV prevention if approved, and this recognition underscores the importance of our scientists’ groundbreaking research and our commitment to help end the HIV epidemic.
-
-
Dale’s story is a reminder that knowledge is a powerful tool in the face of a #BreastCancer diagnosis. We’re proud to work with community partners to educate and empower, so that together we can help address disparities in breast cancer care.
-
People in migrant populations can face legal, social and economic difficulties that make accessing HIV prevention and care services more complicated. We’re announcing a $5+ million commitment in partnership with Charities Aid Foundation (CAF) to drive community-led solutions that help address these gaps in care. Learn more about grant opportunities for organizations working to improve HIV health outcomes for people in migrant populations across Australia, Canada and Europe. https://gilead.inc/3Vl07bN #GileadForGood
-
Verbundene Seiten
Ähnliche Seiten
Aktien
GILD
NASDAQ
Verzögerung von 20 Minuten
92,57 $
1,48 (1,625 %)
- Aktiv
- 90,92
- Niedrig
- 90,71
- Hoch
- 93,29
Daten von Refinitiv
Mehr Informationen aufFinanzierung
Gilead Sciences
Insgesamt 5 Finanzierungsrunden
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdkapital nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
3.500.000,00 $